20.00
price down icon3.01%   -0.62
 
loading
前日終値:
$20.62
開ける:
$20.68
24時間の取引高:
120.51K
Relative Volume:
1.20
時価総額:
$1.32B
収益:
-
当期純損益:
$-143.59M
株価収益率:
-7.0832
EPS:
-2.8236
ネットキャッシュフロー:
$-119.47M
1週間 パフォーマンス:
-16.11%
1か月 パフォーマンス:
+17.65%
6か月 パフォーマンス:
+11.11%
1年 パフォーマンス:
+14.94%
1日の値動き範囲:
Value
$19.88
$20.95
1週間の範囲:
Value
$19.70
$23.63
52週間の値動き範囲:
Value
$11.51
$26.33

Pharvaris Nv Stock (PHVS) Company Profile

Name
名前
Pharvaris Nv
Name
セクター
Healthcare (1164)
Name
電話
-
Name
住所
-
Name
職員
119
Name
Twitter
Name
次回の収益日
2025-07-28
Name
最新のSEC提出書
Name
PHVS's Discussions on Twitter

PHVS を他の銘柄と比較する

株式 価格 時価総額 収益 当期純利益 現金流量 EPS
Biotechnology icon
PHVS
Pharvaris Nv
20.00 1.32B 0 -143.59M -119.47M -2.8236
Biotechnology icon
VRTX
Vertex Pharmaceuticals Inc
460.83 120.60B 11.10B -988.90M -1.26B -3.92
Biotechnology icon
REGN
Regeneron Pharmaceuticals Inc
558.63 60.80B 14.09B 4.50B 2.96B 39.28
Biotechnology icon
ALNY
Alnylam Pharmaceuticals Inc
324.79 42.87B 2.35B -269.70M -75.39M -2.09
Biotechnology icon
ARGX
Argen X Se Adr
595.19 36.23B 2.58B 1.06B -1.28B 16.33
Biotechnology icon
ONC
Beone Medicines Ltd Adr
294.51 31.54B 3.81B -644.79M -669.77M -6.24

Pharvaris Nv Stock (PHVS) Upgrades & Downgrades

日付 アクション アナリスト 評価の変更
2025-06-11 開始されました Guggenheim Buy
2025-04-29 開始されました Cantor Fitzgerald Overweight
2023-09-25 開始されました Wedbush Outperform
2023-08-15 アップグレード Morgan Stanley Equal-Weight → Overweight
2022-10-05 開始されました Bryan Garnier Buy
2022-09-13 再開されました JMP Securities Mkt Outperform
2022-08-23 ダウングレード Morgan Stanley Overweight → Equal-Weight
2022-08-22 ダウングレード BofA Securities Neutral → Underperform
2022-05-25 開始されました JMP Securities Mkt Outperform
2021-03-02 開始されました BofA Securities Neutral
2021-03-02 開始されました Morgan Stanley Overweight
2021-03-02 開始されました Oppenheimer Outperform
2021-03-02 開始されました SVB Leerink Outperform
すべてを表示

Pharvaris Nv (PHVS) 最新ニュース

pulisher
03:40 AM

Volatility clustering patterns for Pharvaris N.V.Trading Watchlist with Real Time Filters - Newser

03:40 AM
pulisher
03:38 AM

Combining machine learning predictions for Pharvaris N.V.AI Stock Movement Forecast with Accuracy - Newser

03:38 AM
pulisher
Jul 28, 2025

Why is Pharvaris N.V. stock attracting strong analyst attentionFinancial News Planner Backed By Experts - jammulinksnews.com

Jul 28, 2025
pulisher
Jul 28, 2025

How to integrate Pharvaris N.V. into portfolio analysis tools Short Term Opportunity Finder with Tools - Newser

Jul 28, 2025
pulisher
Jul 28, 2025

How strong is Pharvaris N.V. company’s balance sheetUnlock your trading potential today - jammulinksnews.com

Jul 28, 2025
pulisher
Jul 28, 2025

What is the dividend policy of Pharvaris N.V. stockConsistently exceptional gains - jammulinksnews.com

Jul 28, 2025
pulisher
Jul 28, 2025

What markets is UKOMW expanding into Is Pharvaris N.V. stock a good long term investment optionInvest confidently with real-time updates - jammulinksnews.com

Jul 28, 2025
pulisher
Jul 28, 2025

Is Pharvaris N.V. a growth stock or a value stockCapitalize on emerging investment opportunities - jammulinksnews.com

Jul 28, 2025
pulisher
Jul 27, 2025

What is Pharvaris N.V. company’s growth strategyFree Advanced Stock Screener Access - jammulinksnews.com

Jul 27, 2025
pulisher
Jul 27, 2025

Pharvaris Announces US$201.2 Million Public Offering of Shares and Pre-Funded Warrants - Global Legal Chronicle

Jul 27, 2025
pulisher
Jul 27, 2025

Is Pharvaris N.V. a Top Dividend Stock to Watch in 2025Free Premium Stock Market Reports - Newser

Jul 27, 2025
pulisher
Jul 27, 2025

New Product Launches: Will They Boost Pharvaris N.V. Stock in 2025High Probability Setups - Newser

Jul 27, 2025
pulisher
Jul 27, 2025

Pharvaris N.V.'s (NASDAQ:PHVS) 11% loss last week hit both individual investors who own 37% as well as institutions - Yahoo.co

Jul 27, 2025
pulisher
Jul 27, 2025

Pharvaris N.V. Stock Performance After Earnings: Historical InsightsFree Access to Community - Newser

Jul 27, 2025
pulisher
Jul 27, 2025

How Interest Rate Changes Impact Pharvaris N.V. Stock PerformanceElite Investor Club - Newser

Jul 27, 2025
pulisher
Jul 27, 2025

How Resilient Is Pharvaris N.V. Stock During Economic DownturnsHigh Return Potential - Newser

Jul 27, 2025
pulisher
Jul 26, 2025

What makes Pharvaris N.V. stock price move sharplyPro Trader Stock Focus - metal.it

Jul 26, 2025
pulisher
Jul 25, 2025

What analysts say about Pharvaris N.V. stockRecord-setting profit potential - Autocar Professional

Jul 25, 2025
pulisher
Jul 25, 2025

Pharvaris' $201.2M Funding: A Strategic Catalyst for HAE Treatment Innovation and Shareholder Value - AInvest

Jul 25, 2025
pulisher
Jul 25, 2025

Pharvaris N.V. Stock Analysis and ForecastDynamic investment opportunities - PrintWeekIndia

Jul 25, 2025
pulisher
Jul 25, 2025

How Pharvaris N.V. stock performs during market volatilityFree Short-Term Stock Picks - Newser

Jul 25, 2025
pulisher
Jul 25, 2025

How Pharvaris N.V. stock reacts to Fed policy changesRapidly growing investment returns - jammulinksnews.com

Jul 25, 2025
pulisher
Jul 24, 2025

Pharvaris Raises $201 Million in Successful Offering - TipRanks

Jul 24, 2025
pulisher
Jul 24, 2025

Pharvaris Announces Closing of $201.2 Million Upsized Public Offering of Ordinary Shares and Pre-Funded Warrants and Full Exercise of Underwriters’ Option to Purchase Additional Shares - The Manila Times

Jul 24, 2025
pulisher
Jul 24, 2025

Pharvaris Secures Massive $201M Public Offering: HAE Drug Developer Sees Strong Investor Demand - Stock Titan

Jul 24, 2025
pulisher
Jul 23, 2025

Is Pharvaris N.V. a good long term investmentRapid growth opportunities - Autocar Professional

Jul 23, 2025
pulisher
Jul 23, 2025

Pharvaris: Deucrictibant Advanced To Target Two Sets Of HAE Patient Populations (PHVS) - Seeking Alpha

Jul 23, 2025
pulisher
Jul 23, 2025

What drives Pharvaris N.V. stock priceHigh-yield capital appreciation - jammulinksnews.com

Jul 23, 2025
pulisher
Jul 23, 2025

Pharvaris shares slide following $175 million equity offering - MSN

Jul 23, 2025
pulisher
Jul 23, 2025

Pharvaris stock drops after pricing $175 million public offering By Investing.com - Investing.com Canada

Jul 23, 2025
pulisher
Jul 23, 2025

Pharvaris stock drops after pricing $175 million public offering - Investing.com Australia

Jul 23, 2025
pulisher
Jul 23, 2025

Pharvaris' $175M Equity Raise: A Strategic Catalyst for HAE Market Leadership - AInvest

Jul 23, 2025
pulisher
Jul 22, 2025

Pharvaris' $175M Equity Raise: Fueling a Strategic Leap in the HAE Market - AInvest

Jul 22, 2025
pulisher
Jul 22, 2025

Pharvaris prices $175 million public offering to fund angioedema programs By Investing.com - Investing.com India

Jul 22, 2025
pulisher
Jul 22, 2025

Pharvaris Announces Pricing of Upsized $175 Million Public Offering of Ordinary Shares and Pre-Funded Warrants - The Manila Times

Jul 22, 2025
pulisher
Jul 22, 2025

Pharvaris prices $175 million public offering to fund angioedema programs - Investing.com

Jul 22, 2025
pulisher
Jul 22, 2025

Pharvaris Secures Massive $175M Public Offering to Advance Oral HAE Treatment Pipeline - Stock Titan

Jul 22, 2025
pulisher
Jul 22, 2025

Pharvaris Announces Pricing of Upsized $175 Million Public Offering of Ordinary Shares and Pre-Funded Warrants - GlobeNewswire Inc.

Jul 22, 2025

Pharvaris Nv (PHVS) 財務データ

収益

loading

当期純利益

loading

現金流量

loading

EPS

loading
$23.09
price down icon 1.32%
$37.06
price up icon 1.06%
$101.75
price down icon 2.12%
$27.45
price down icon 4.26%
$112.79
price down icon 2.19%
biotechnology ONC
$294.51
price up icon 1.04%
大文字化:     |  ボリューム (24 時間):